IMUC (EOM Pharmaceutical Holdings) Stock Based Compensation: $0.28 Mil (TTM As of Jun. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is EOM Pharmaceutical Holdings Stock Based Compensation?

EOM Pharmaceutical Holdings IMUC Stock Based Compensation is $0.28 Mil as of Jun. 2018.

EOM Pharmaceutical Holdings's Stock Based Compensation for the three months ended in Jun. 2018 was $0.06 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2018 was $0.28 Mil.

EOM Pharmaceutical Holdings Stock Based Compensation Related Terms

EOM Pharmaceutical Holdings Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for EOM Pharmaceutical Holdings's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EOM Pharmaceutical Holdings Stock Based Compensation Chart

EOM Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.72 0.65 0.92 1.23 0.49

EOM Pharmaceutical Holdings Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.12 0.05 0.05 0.06

EOM Pharmaceutical Holdings Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.28 Mil.

What does a Stock Based Compensation of $0.28 Mil mean?
EOM Pharmaceutical Holdings (IMUC) has a Stock Based Compensation of $0.28 Mil as of Jun. 2018. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for EOM Pharmaceutical Holdings and its competitors.
Is EOM Pharmaceutical Holdings' Stock Based Compensation too high?
EOM Pharmaceutical Holdings' current Stock Based Compensation is $0.28 Mil.
How does EOM Pharmaceutical Holdings' Stock Based Compensation compare to MNTMD and RTTR?
EOM Pharmaceutical Holdings' Stock Based Compensation of $0.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for EOM Pharmaceutical Holdings and its competitors. EOM Pharmaceutical Holdings's current Stock Based Compensation is $0.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EOM Pharmaceutical Holdings stock overvalued right now?
EOM Pharmaceutical Holdings (IMUC) has a current Stock Based Compensation of $0.28 Mil. The current Stock Based Compensation is $0.28 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For EOM Pharmaceutical Holdings (IMUC), the current Stock Based Compensation is $0.28 Mil as of Jun. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EOM Pharmaceutical Holdings Business Description

Address 136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is a clinical-stage biotechnology company that is focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. Its products have been approved in the U.S., rheumatoid arthritis, and inflammatory conditions of the gastrointestinal tract such as Crohn's Disease and Ulcerative Colitis as well as various retina disorders characterized by a breakdown of the blood-retinal barrier such as diabetic retinopathy, Aged related macular degeneration and retinal vein occlusion among others. Its pipeline includes its compound EOM613, an investigational novel dynamically dual-acting immunomodulator.